

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A composition for inhibiting proteinase activated receptor activity comprising a protein, peptide, biomolecule or active fragment thereof.
2. (Previously Presented) The composition of Claim 1, wherein the proteinase activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.
3. (Previously Presented) The composition of Claim 1, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID NO:22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 or active fragments thereof.
4. (Previously Presented) The composition of Claim 3, wherein the proteinase activated receptor comprises PAR-2.
5. (Previously Presented) The composition of Claim 1, wherein the proteinase activated receptor comprises PAR-2 and wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

6. (Previously Presented) The composition of Claim 1, wherein the proteinase activated receptor comprises PAR-2 and wherein the protein, peptide, or biomolecule comprises ENMD 547.

7. (Original) The composition of Claim 1, further comprising a pharmaceutically acceptable carrier.

8. (Withdrawn-Previously Amended) A method for inhibiting proteinase activated receptor activity in a subject comprising administering to said subject the composition of Claim 1 comprising a protein, peptide, biomolecule or active fragment thereof.

9. (Withdrawn- Previously Amended) The method of Claim 8, wherein the proteinase activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.

10. (Withdrawn- Previously Amended) The method of Claim 8, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID NO:22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 or active fragments thereof.

11. (Withdrawn-Previously Amended) The method of Claim 8, wherein the proteinase activated receptor comprises PAR-2.

12. (Withdrawn- Previously Amended) The method of Claim 8, wherein the proteinase activated receptor comprises PAR-2 and wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

13. (Withdrawn- Previously Amended) The method of Claim 8, wherein the proteinase activated receptor comprises PAR-2 and wherein the protein, peptide, or biomolecule comprises ENMD 547.

14. (Withdrawn) The method of Claim 8, further comprising a pharmaceutically acceptable carrier.

15. (Withdrawn- Previously Amended) A method for treating a disorder associated with abnormal proteinase activated receptor activity comprising administering to a subject in need of such treatment, the composition of Claim 1 comprising a protein, peptide, biomolecule or active fragment thereof capable of inhibiting proteinase activated receptor activity.

16. (Withdrawn-Previously Amended) The method of Claim 15, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID NO:22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 or active fragments thereof.

17. (Withdrawn-Previously Amended) The method of Claim 15, wherein the disorder comprises an angiogenic disease, undesirable neovascularization, inflammation, tumor growth, sepsis, neurogenic inflammatory pain, asthma, post operative ileus or cancer.

18. (Withdrawn) The method of Claim 17, wherein the disorder comprises inflammation and wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

19. (Withdrawn) The method of Claim 17, wherein the disorder comprises inflammation and wherein the protein, peptide, or biomolecule comprises ENMD 547.

20. (Withdrawn-Previously Amended) The method of Claim 15, further comprising a pharmaceutically acceptable carrier.